glp-1 weight loss drug market news today Retatrutide for loss: Study shows 30% body weight New weight-loss drugs surge in

Description

A variant associated with stronger GLP1R signaling predisposition does not guarantee superior weight loss on semaglutide or tirzepatide

More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling

In general, GLP-1 agonists promote weight loss through the following two mechanisms: Suppression of appetite and cravings: These medications target the brain to curtail appetite so one can achieve satiety with small portions of food

Current Landscape As of 2024, exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide are the globally available GLP-1-RAs

#HealthTech #Biotech #GLP1 #Tirzepatide#PharmaNews #Incretins #WeightManagement #DiabetesCare #FutureOfMedicine #Retatrutide #Pharmacology #Endocrinology #Biotechnology #ClinicalTrials #ObesityMedicine #Pharmaceuticals To view or add a comment, sign in Why does Lilly continue to invest in obesity pipelines after Zepbound